Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.49 |
| ▸ | CNR1 | P21554 | 7/20 | 0.49 |
| ▸ | LIPE | Q05469 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12875690 | 0.90 | CHRNB2 (0.50) | CNR2CNR1LIPE | |
| SCHEMBL12875711 | 0.82 | LIPE (0.43) | CNR2CNR1LIPEEPHX2DCTPP1 | |
| SCHEMBL12875713 | 0.81 | LIPE (0.42) | CNR2CNR1LIPEEPHX2TP53 | |
| SCHEMBL1147138 | 0.76 | MAPT (0.46) | CNR2CNR1FAAHEPHX2TP53 | |
| SCHEMBL12085011 | 0.75 | LIPE (0.58) | LIPEFAAHEPHX2TP53 | |
| SCHEMBL1147173 | 0.75 | EPHX2 (0.55) | LIPEEPHX2TP53 | |
| SCHEMBL1147162 | 0.75 | HSD11B1 (0.46) | CNR2CNR1FAAHEPHX2TP53 | |
| SCHEMBL12874915 | 0.75 | EPHX2 (0.52) | EPHX2GAA | |
| SCHEMBL12874912 | 0.75 | FAAH (0.48) | FAAHTP53GAA | |
| SCHEMBL12875147 | 0.73 | MEN1 (0.51) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011012602-A1 | PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-03 | — | — | WO | disclosed |